Page last updated: 2024-12-10

sq 109

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5274428
CHEMBL ID561057
SCHEMBL ID1780848
SCHEMBL ID1780846
SCHEMBL ID10050752
SCHEMBL ID19630696
MeSH IDM0493786

Synonyms (48)

Synonym
n-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-n'-[(1r,3s,5r,7r)-tricyclo[3.3.1.1~3,7~]dec-2-yl]ethane-1,2-diamine
sq-109
1,2-ethanediamine, n-[(2e)-3,7-dimethyl-2,6-octadienyl]-n'-tricyclo[3.3.1.13,7]dec-2-yl-
nsc722041
n'-(2-adamantyl)-n-[(2e)-3,7-dimethylocta-2,6-dienyl]ethane-1,2-diamine
sq109
CHEMBL561057 ,
nsc-722041
502487-67-4
n-geranyl-n'-(2-adamantyl)ethane-1,2-diamine
9au7xuv31a ,
nsc 722041
sq 109
1,2-ethanediamine, n1-((2e)-3,7-dimethyl-2,6-octadien-1-yl)-n2-tricyclo(3.3.1.13,7)dec-2-yl-
unii-9au7xuv31a
bdbm50388398
HY-14989
CS-1188
gtpl7997
DB05186
n-adamantanyl-n'-geranyl-ethylenediamine
1,2-ethanediamine, n-((2e)-3,7-dimethyl-2,6-octadienyl)-n'-tricyclo(3.3.1.13,7)dec-2-yl-
SCHEMBL1780848
SCHEMBL1780846
SCHEMBL10050752
AC-31289
J-690310
EX-A764
AKOS030526825
sq109, >=98% (hplc)
SCHEMBL19630696
n1-((1r,5r,7s)-adamantan-2-yl)-n2-((e)-3,7-dimethylocta-2,6-dien-1-yl)ethane-1,2-diamine
n-[(2e)-3,7-dimethyl-2,6-octadienyl]-n ?-tricyclo[3.3.1.13,7]dec-2-yl-1,2-ethanediamine
n-[(2e)-3,7-dimethyl-2,6-octadienyl]-n inverted exclamation marka-tricyclo[3.3.1.13,7]dec-2-yl-1,2-ethanediamine
n1-(adamantan-2-yl)-n2-(3,7-dimethylocta-2,6-dien-1-yl)ethane-1,2-diamine
JFIBVDBTCDTBRH-REZTVBANSA-N
(e)-n1-(adamantan-2-yl)-n2-(3,7-dimethylocta-2,6-dien-1-yl)ethane-1,2-diamine
Q7392720
n1-[(2e)-3,7-dimethyl-2,6-octadien-1-yl]-n2-tricyclo[3.3.1.13,7]dec-2-yl-1,2-ethanediamine
DTXSID30964540
Q27454083
MS-24974
A857589
n-[(2e)-3,7-dimethyl-2,6-octadienyl]-n'-tricyclo[3.3.1.1(3,7)]dec-2-yl-1,2-ethanediamine
CVA48767
sq 109 deuterated
PD119643
PD062226

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" equivalent body surface area dose, the terminal half-life (t1/2) of SQ109 in dogs was longer than that in rodents, reflected by a larger volume of distribution (Vss) and a higher clearance rate of SQ109 in dogs, compared to that in rodents."( Interspecies pharmacokinetics and in vitro metabolism of SQ109.
Coward, L; Gorman, GS; Jia, L; Noker, PE; Protopopova, M; Tomaszewski, JE, 2006
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" This first study in patients was done to determine safety, tolerability, pharmacokinetics and bacteriological effect of different doses of SQ109 alone and in combination with rifampicin when administered over 14 days."( Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Aarnoutse, RE; Boeree, MJ; Dawson, R; Diacon, AH; du Bois, J; Gillespie, SH; Heinrich, N; Henne, S; Hoelscher, M; Horwith, G; Nacy, CA; Narunsky, K; Phillips, PP; Phipps, AJ; Rachow, A; Venter, A, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"The low bioavailability of SQ109 in rats, resulting from first-pass effect in the liver, may be remedied by prodrug strategy."( Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
Li, W; Liu, Y; Luo, H; Meng, Q; Yao, Q; Zhang, W, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4,4'-diapophytoene synthaseStaphylococcus aureusKi0.36000.36000.93001.5000AID672791
Geranylgeranyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)4.50000.00401.02764.5000AID1138403
Translocator proteinRattus norvegicus (Norway rat)Ki0.36000.00010.65108.9300AID672791
Squalene synthaseHomo sapiens (human)IC50 (µMol)100.00000.07802.14788.0000AID1138405
Squalene synthaseHomo sapiens (human)Ki0.74000.74000.74000.7400AID672792
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)5.50000.00401.966610.0000AID1873198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
isoprenoid metabolic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranylgeranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
isoprenoid biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
steroid biosynthetic processSqualene synthaseHomo sapiens (human)
farnesyl diphosphate metabolic processSqualene synthaseHomo sapiens (human)
cholesterol biosynthetic processSqualene synthaseHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
dimethylallyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
identical protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
prenyltransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activitySqualene synthaseHomo sapiens (human)
protein bindingSqualene synthaseHomo sapiens (human)
metal ion bindingSqualene synthaseHomo sapiens (human)
farnesyl-diphosphate farnesyltransferase activitySqualene synthaseHomo sapiens (human)
squalene synthase activitySqualene synthaseHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytosolGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
Z discGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
perinuclear region of cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
endoplasmic reticulumSqualene synthaseHomo sapiens (human)
endoplasmic reticulum membraneSqualene synthaseHomo sapiens (human)
membraneSqualene synthaseHomo sapiens (human)
endoplasmic reticulum membraneSqualene synthaseHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID1138388Antimicrobial activity against Bacillus subtilis subsp. subtilis ATCC 6051 after 12 to 16 hrs by microbroth dilution method2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138387Antimicrobial activity against Mycobacterium smegmatis ATCC 7000842014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1162179Oral bioavailability in mouse2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID672791Inhibition of Staphylococcus aureus ATCC 27659 dehydrosqualene synthase expressed in Escherichia coli BL21(DE3) after 30 mins by spectrophotometric analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Head-to-head prenyl tranferases: anti-infective drug targets.
AID449436Cytotoxicity against MDBK cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents.
AID1296081Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATTC 27294 assessed as inhibition of mycobacterial growth incubated for 7 days2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1296078Antimycobacterial activity against Mycobacterium aurum ATCC 23366 assessed as inhibition of mycobacterial growth incubated for 4 days2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID426579Oral bioavailability in rat2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID700840Antimicrobial activity against Mycobacterium tuberculosis H37Rv2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID1296083Antimycobacterial activity against drug-resistant Mycobacterium tuberculosis isolate MDR2 assessed as inhibition of mycobacterial growth incubated for 9 days2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138402Inhibition of Staphylococcus aureus farnesyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1296080Antimycobacterial activity against Mycobacterium tuberculosis mc'2-7000x assessed as inhibition of mycobacterial growth2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID698845Antimycobacterial activity against Mycobacterium tuberculosis infected in mouse assessed as log reduction of CFU in spleen at 10 to 25 mg/kg after 30 days2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID1296091Selectivity index, ratio of GIC50 for cytotoxicity against human THP1 cells to MIC for Mycobacterium tuberculosis H37Rv ATTC 272942016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138400Inhibition of Staphylococcus aureus undecaprenyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID426590Oral bioavailability in rat at 13 mg/kg2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID698839Half life in human up to 300 mg, po2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID426582Half life in rat at 1.5 mg/kg, iv2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1138398Inhibition of Mycobacterium tuberculosis cis-decaprenyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138385Antimicrobial activity against Mycobacterium tuberculosis H37Rv2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID698975Antimycobacterial activity against EMB-resistant Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID478538Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis XDR 173 by BACTEC 460 radiometric method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.
AID1138401Inhibition of Escherichia coli undecaprenyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138391Antimicrobial activity against Saccharomyces cerevisiae ATCC 208352 after 48 hrs by microbroth dilution method2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1296077Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC 35734 assessed as inhibition of mycobacterial growth incubated for 24 hrs by MABA method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1871982Antimycobacterial activity against Mycobacterium tuberculosis2022European journal of medicinal chemistry, Feb-05, Volume: 229Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID581011Plasma protein binding in CD2F1 mouse at 0.1 to 2.5 ug/ml by ultracentrifugation2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1138394Cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID698843Oral bioavailability in mouse at 10 mg/kg2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID581008Plasma protein binding in human at 0.1 to 2.5 ug/ml by ultracentrifugation2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1296075Antimicrobial activity against Mycobacterium tuberculosis2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138384Inhibition of Mycobacterium tuberculosis MenA2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID426587Half life in rat at 13 mg/kg, po2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID672792Inhibition of human squalene synthase2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Head-to-head prenyl tranferases: anti-infective drug targets.
AID1138410Inhibition of Escherichia coli N-terminal strep-tagged MenA expressed in Escherichia coli C43 (DE3) assessed as demethylmenaquinone-3 formation after 30 mins by HPLC analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1296076Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 ATCC 700084 assessed as inhibition of mycobacterial growth incubated for 24 hrs by MABA method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID426589AUC(0 to 24 hrs) in rat at 13 mg/kg, po2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1296090Selectivity index, ratio of GIC50 for cytotoxicity against mouse RAW264.7 cells to MIC for Mycobacterium tuberculosis H37Rv ATTC 272942016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138407Inhibition of Mycobacterium smegmatis MenG using radiolabeled S-adenosylmethionine as substrate after 1 hr by liquid scintillation counting analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138389Antimicrobial activity against methicillin-resistant Staphylococcus aureus USA3002014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138409Disruption of membrane potential in Mycobacterium smegmatis by DisC3(5) probe-based fluorescence spectrophotometry2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID698974Antimycobacterial activity against INH-resistant Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID426584AUC(0 to 24 hrs) in rat at 1.5 mg/kg, iv2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1659811Antitubercular activity against Mycobacterium tuberculosis harboring mmpL32020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Molecule Property Analyses of Active Compounds for
AID1138412Antimicrobial activity against Mycobacterium tuberculosis H37Rv incubated for 7 days measured after 28 days by resazurin microplate reduction assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID426586Tmax in rat at 13 mg/kg, po2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1138392Antimicrobial activity against Candida albicans CAI-42014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1883681Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID426581Cmax in rat at 1.5 mg/kg, iv2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID581002Antimicrobial activity against compound-susceptible Mycobacterium tuberculosis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1138404Inhibition of Staphylococcus aureus CrtM2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1162172Antitubercular activity against drug-resistant Mycobacterium tuberculosis clinical isolates assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID698846Antimycobacterial activity against Mycobacterium tuberculosis infected in mouse assessed as log reduction of CFU in lung at 10 to 25 mg/kg after 30 days2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID1138426Inhibition of Mycobacterium smegmatis lactate dehydrogenase using lactate as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID581009Plasma protein binding in Beagle dog at 0.1 to 2.5 ug/ml by ultracentrifugation2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID698847Antimycobacterial activity against RIF-resistant Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID581007Antimicrobial activity against compound-resistant Mycobacterium tuberculosis2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1138397Inhibition of Mycobacterium tuberculosis cis-farnesyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138416Antimicrobial activity against nonreplicating streptomycin-starved Mycobacterium tuberculosis 18b at 10 ug/ml incubated for 7 days measured after 28 days by resazurin microplate reduction assay in presence of MK-42014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138427Induction of collapse in deltapH in Mycobacterium smegmatis inverted membrane vesicles at 30 to 150 uM by 31P NMR spectroscopy2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID449434Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in MDBK by BACTEC analysis2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents.
AID1296088Cytotoxic activity against human THP1 cells assessed as reduction in cell viability incubated for 48 hrs by trypan blue based assay2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138414Antimicrobial activity against Mycobacterium tuberculosis H37Rv incubated for 7 days measured after 28 days by resazurin microplate reduction assay in presence of MK-42014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1873198Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID672790Inhibition of Trypanosoma cruzi squalene synthase2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Head-to-head prenyl tranferases: anti-infective drug targets.
AID1162177Oral bioavailability in dog2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1296089Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by trypan blue based assay2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138403Inhibition of human geranylgeranyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138422Inhibition of Mycobacterium smegmatis electron transport protein complex 1 using NADH as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID426580Oral bioavailability in dog2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1138417Antimicrobial activity against nonreplicating streptomycin-starved Mycobacterium tuberculosis 18b assessed as log reduction at 10 ug/ml incubated for 7 days measured after 28 days by resazurin microplate reduction assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138408Inhibition of respiration in Mycobacterium smegmatis after 5 mins by methylene blue reduction assay in presence of NADH2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138396Ratio of IC50 for Escherichia coli ATCC 29425 in presence of 10% fetal bovine serum to IC50 for Escherichia coli ATCC 294252014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138399Inhibition of Plasmodium vivax geranylgeranyl diphosphate synthase2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1604181Antileishmanial activity against Leishmania mexicana intracellular amastigotes infected in J774 macrophages assessed as reduction in parasite viability after 72 hrs2019European journal of medicinal chemistry, Dec-01, Volume: 183Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
AID1138386Antimicrobial activity against Mycobacterium tuberculosis ATCC 272942014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID581010Plasma protein binding in Fischer rat at 0.1 to 2.5 ug/ml by ultracentrifugation2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID637876Ratio of ethambutol dihydrochloride MIC to compound MIC for Mycobacterium tuberculosis H37Rv2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and in vitro antimycobacterial activity of compounds derived from (R)- and (S)-2-amino-1-butanol - The crucial role of the configuration.
AID698844AUC in mouse at 25 mg/kg, po2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID426583Clearance in rat at 1.5 mg/kg, iv2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1138425Inhibition of Mycobacterium smegmatis succinate dehydrogenase using succinate as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID698842Tmax in mouse at 25 mg/kg, po2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID1138406Inhibition of Mycobacterium smegmatis MenA2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID700839Volume of distribution in mouse2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID698995Antimycobacterial activity against drug-sensitive Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID1138421Therapeutic index, ratio of IC50 for human MCF7 cells to MIC for Mycobacterium tuberculosis ATCC 272942014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1162178Oral bioavailability in rat2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1138424Inhibition of Mycobacterium smegmatis electron transport protein complex 1 using deamino-NADH as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID698841Cmax in mouse at 25 mg/kg, po2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID1138390Antimicrobial activity against Escherichia coli ATCC 29425 after 3 hrs by microbroth dilution method2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138415Antimicrobial activity against nonreplicating streptomycin-starved Mycobacterium tuberculosis 18b at 1 ug/ml incubated for 7 days measured after 28 days by resazurin microplate reduction assay in presence of MK-42014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138411Induction of collapse in deltapH in Escherichia coli inverted membrane vesicles by 31P NMR spectroscopy2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138395Therapeutic index, ratio of IC50 for human MCF7 cells to IC50 for Plasmodium falciparum 3D72014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1288657Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by 2-fold broth dilution method
AID1296092Inhibition of multidrug resistance efflux pump in Mycobacterium aurum ATCC 23366 assessed as inhibition of ethidium bromide efflux by measuring relative fluorescence units for ethidium bromide accumulation at 1/4 times MIC incubated for 60 mins by fluorim2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID1138418Inhibition of Mycobacterium smegmatis malate dehydrogenase using malate as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138413Antimicrobial activity against nonreplicating streptomycin-starved Mycobacterium tuberculosis 18b at 1 ug/ml incubated for 7 days measured after 28 days by resazurin microplate reduction assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1138393Antimicrobial activity against Plasmodium falciparum 3D7 by intraerythrocytic assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID478537Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 25618 by BACTEC 460 radiometric method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.
AID1138405Inhibition of human SQS2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1162175Antitubercular activity against drug-susceptible Mycobacterium tuberculosis clinical isolates assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1296082Antimycobacterial activity against drug-resistant Mycobacterium tuberculosis isolate MDR1 assessed as inhibition of mycobacterial growth incubated for 9 days2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
AID744647Antimycobacterial activity against Mycobacterium tuberculosis assessed as growth inhibition2013European journal of medicinal chemistry, May, Volume: 63Efficient synthesis of new (R)-2-amino-1-butanol derived ureas, thioureas and acylthioureas and in vitro evaluation of their antimycobacterial activity.
AID426588Clearance in rat at 13 mg/kg, po2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1883680Antibacterial activity against EMB-resistant Mycobacterium tuberculosis assessed as inhibition of bacterial growth2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Tuberculosis Drug Discovery: Challenges and New Horizons.
AID426585Cmax in rat at 13 mg/kg, po2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
AID1138423Inhibition of Mycobacterium smegmatis NADH dehydrogenase using NDH2 as substrate by MTT assay2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID1346881Human squalene synthase (Lanosterol biosynthesis pathway)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Head-to-head prenyl tranferases: anti-infective drug targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (19.64)29.6817
2010's34 (60.71)24.3611
2020's11 (19.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.09 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index57.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (5.17%)5.53%
Reviews21 (36.21%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (58.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]